In recent years, protein therapeutics have made rapid progress in the treatment of human diseases. However, they are often hindered by issues such as short plasma half-life, high immunogenicity, low solubility, and susceptibility to enzymatic degradation. Introducing polyethylene glycol (PEG) to biomolecules and therapeutics can enhance the stability and pharmacological properties of proteins, peptides, antibody-drug conjugates, and small molecule drugs.

PEG is a highly hydrophilic synthetic polymer. Modifying protein molecules with PEG can alter their spatial conformation, thereby improving various biochemical properties. These include increased chemical stability, enhanced resistance to proteolysis, reduced or eliminated immunogenicity and toxicity, and decreased plasma clearance rates. As such, PEGylation is widely used to extend the circulation time of proteins, enhance the solubility of therapeutic molecules, reduce immunogenicity, and optimize pharmacokinetic profiles, making it an effective strategy for improving biopharmaceuticals.

Figure 1. PEG (Polyethylene Glycol) Modification of Proteins, Peptides, and Small Molecules

PEGylation can increase protein solubility and stability, alter pharmacokinetic properties, and reduce immunogenicity. We offer comprehensive protein PEGylation services including: